CalciMedica Inc. (NASDAQ:CALC) Short Interest Update

CalciMedica Inc. (NASDAQ:CALC) saw a large drop in short interest during the month of April. As of April 30th, there was short interest totaling 167,953 shares, a drop of 54.9% from the April 15th total of 372,157 shares. Approximately 1.8% of the company’s shares are short sold. Based on an average daily volume of 151,788 shares, the days-to-cover ratio is currently 1.1 days.

CalciMedica Stock Performance

CALC stock traded up $0.00 during mid-day trading on Friday, hitting $0.68. 215,416 shares of the company were exchanged, compared to its average volume of 881,419. The firm has a market cap of $10.78 million, a P/E ratio of -0.52 and a beta of 0.85. The firm’s 50 day simple moving average is $0.64 and its 200 day simple moving average is $2.52. CalciMedica has a 1-year low of $0.46 and a 1-year high of $7.20.

CalciMedica (NASDAQ:CALC) last announced its earnings results on Tuesday, March 3rd. The company reported ($0.69) EPS for the quarter. On average, equities research analysts predict that CalciMedica will post -1.21 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CALC. Wall Street Zen raised shares of CalciMedica to a “sell” rating in a research note on Saturday, January 17th. Oppenheimer reduced their target price on shares of CalciMedica from $20.00 to $10.00 and set an “outperform” rating on the stock in a research note on Thursday, March 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a research note on Wednesday, January 21st. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Thursday, January 29th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CalciMedica currently has an average rating of “Hold” and an average target price of $10.00.

Institutional Trading of CalciMedica

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its holdings in CalciMedica by 45.0% during the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after buying an additional 39,775 shares during the period. 180 Wealth Advisors LLC raised its holdings in shares of CalciMedica by 297.2% in the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock valued at $68,000 after purchasing an additional 94,650 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the last quarter. Boothbay Fund Management LLC acquired a new stake in shares of CalciMedica in the fourth quarter valued at approximately $506,000. Finally, Meritage Portfolio Management raised its holdings in shares of CalciMedica by 33.8% in the third quarter. Meritage Portfolio Management now owns 61,539 shares of the company’s stock valued at $189,000 after purchasing an additional 15,539 shares during the last quarter.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.